Physician profile
Timothy L Lyons
NPI 1164636825
$10,619.89
in general payments reported to CMS, 2019-2025
46 companies · $1,364 in 2025
The $1,364 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,503 · 2020: $1,157 · 2021: $1,531 · 2022: $1,604 · 2023: $1,770 · 2024: $1,690 · 2025: $1,364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,825.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,825.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,695.98 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,564.74 | 2019-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $1,477.00 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Janssen Pharmaceuticals, INC | $1,047.98 | 2019-2025 | Spravato, Xarelto |
| Abbvie INC. | $897.69 | 2019-2025 | |
| Glaxosmithkline, LLC. | $401.30 | 2019-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $383.31 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $380.43 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $279.16 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $226.36 | 2019-2024 | Jardiance |
| Neurocrine Biosciences, INC. | $210.02 | 2023-2025 | Ingrezza, Ongentys |
| Aimmune Therapeutics, INC. | $173.47 | 2024-2025 | Zenpep |
| Novartis Pharmaceuticals Corporation | $159.76 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $146.17 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $122.89 | 2023-2025 | Gemtesa |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Lyons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.